No Data
Contemporary Amperex Technology and other Battery manufacturers compete with new products as the supercharging and fast charging storm approaches | New forces at the auto show.
① Battery manufacturers took center stage at the auto show, with Contemporary Amperex Technology, Sunwoda Electronic, and Eve Energy Co., Ltd. competing with new products at the Shanghai Auto Show; ② A storm of ultra-fast charging has arrived, with megawatt fast-charging products from companies like BYD, Huawei, and ZEEKR showcased at the auto show.
When Autos "roll" towards the sky: Xpeng Huitian, Fengfei, GAC and others showcase eVTOL for the first time at the Shanghai Auto Show | New Forces in the Auto Show.
① The 2-ton level eVTOL from Fengfei Aviation, Xiaopeng Huitian's "land aircraft carrier", and GAC high domain's GOVY-Aircar all made their appearance at the Shanghai Auto Show; ② Reports indicate that these manufacturers' eVTOLs/flying cars are making their debut at the Shanghai Auto Show.
The Shanghai Auto Show witnesses the "mutual rush" of Chinese and foreign enterprises: multinational car companies are deeply cultivating the Chinese market while domestic supply chain enterprises are accelerating their move towards Global.
① The 2025 Shanghai Auto Show focuses on smart electric vehicles, with foreign car companies accelerating their integration into the China supply chain, and local innovative forces rising; ② Under the pressure of transformation, Toyota deepens its local layout by establishing a wholly-owned factory in Shanghai, betting on localization and supply chain synergy; ③ Joint venture brands strengthen collaboration in local innovation chains, as China supply chain companies accelerate their dominance in the Global smart electric vehicle industry.
BYD: In Q1, revenue and net profit both saw growth, with the New energy Fund driving record performance.
BYD Q1 revenue and net profit both increased: New energy Fund driven record performance, expanding production to prepare for Global market. Key points: Strong performance growth: Q1...
Jiangsu Hengrui Pharmaceuticals: Authorized revenue becomes the "accelerator" for performance.
Personnel, products, and research and development are gradually becoming Global.
The upfront payment for the new ADC drug has boosted revenue, Jiangsu Hengrui Pharmaceuticals' Q1 revenue increased by 20.14% year-on-year, and net income increased by 36.9% | Earnings Reports insights.
In Q1, Jiangsu Hengrui Pharmaceuticals' revenue increased by 20.14% year-on-year, net income attributable to the parent company increased by 36.9%, and net income after deductions increased by 29.35% year-on-year. The significant increase in net income was primarily due to the company receiving a $75 million upfront payment for external licensing.
